Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
Research ArticleCurrent Practice

Folic acid and prevention of neural tube defects

Milly Ryan-Harshman and Walid Aldoori
Canadian Family Physician January 2008, 54 (1) 36-38;
Milly Ryan-Harshman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walid Aldoori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

QUESTION Now that flour and pasta have been fortified with folic acid in Canada, do I still need to recommend folic acid supplements to my patients who are of child-bearing age? If I should recommend supplements, when should I recommend them, and what is an appropriate dose?

ANSWER Non-pregnant women should consume 400 μg of folic acid daily, and pregnant women should consume 600 μg of folic acid daily. Mean intakes of folate in Canada before fortification were around 200 μg/d or less. Fortification increased intake of folic acid by up to 100 μg/d. You should discuss the importance of folic acid with your patients who are planning pregnancy; it is recommended that a folic acid supplement or prenatal multivitamin containing at least 400 μg of folic acid be consumed daily. The upper limit for folic acid is 1 mg/d. Women in intermediate- to high-risk categories for neural tube defects, such as a previous neural tube defect–affected pregnancy, should take 4 to 5 mg of folic acid daily.

Maternal folate status is involved in the pathogenesis of neural tube defects (NTDs), and although the exact mechanism is not clear, a nutritional or genetic defect in homocysteine metabolism via methionine synthase appears likely. Women who previously had infants with NTDs were found to have had higher plasma homo-cysteine levels than women who had normal offspring.1,2

Higher homocysteine levels can be indicative of the presence of a metabolic defect that increases risk of NTDs or other congenital defects. The rapidly dividing cells of the neural tube can be particularly sensitive to folate because of its importance to methyl group metabolism in nucleic acid and amino acid biosynthesis.3

Certainly, the scientific evidence that folic acid taken around the time of conception prevents many NTDs has been very strong.4 In Canada starting in January 1998, flour and pasta were fortified with folic acid to help prevent NTDs, and results have been very encouraging.5 In Europe, recommendations to increase folic acid through voluntary supplementation did not reduce the incidence of NTDs; however, food fortification had not been implemented.6 Interestingly enough, however, when physicians took an active role in promoting folic acid supplementation, folic acid intake increased. Women who received folic acid counseling, a 30-day supply of folic acid tablets, and a reminder telephone call increased their folic acid intake by 68%, compared with 20% of controls who received only a pamphlet on folic acid.7

Periconceptional use of folic acid has been shown to reduce the incidence of non-NTD birth defects, such as cleft palates, upper limb reduction deficits, and genitourinary defects.8 Others have also observed a link between folic acid and congenital heart defects, urinary tract anomalies, orofacial clefts, limb defects, and pyloric stenosis.9

Recommendations on folic acid supplementation

Before fortification, mean intakes of folate in Canada were less than 200 μg/d, though folate content in foods generally has been underestimated. United States data placed the average folate intake at about 250 μg/d.10 Fortification increases dietary consumption by up to 100 μg/d or about 25% of the recommended daily allowance.11 During pregnancy, folic acid should be increased to 600 μg/d.10 Many pregnancies are unplanned, and women often do not know that they are pregnant until the crucial first 4 to 8 weeks of pregnancy. This is the time during which neural tube development occurs, hence the importance of ensuring adequate folic acid intake. Therefore, to achieve the greatest benefit in NTD risk reduction, women of child-bearing age should be consuming total folic acid intakes of at least 400 μg, and probably 600 μg, daily. A daily supplement of 400 μg of folic acid should remain an important component of NTD prevention.12

Some individuals might have a greater requirement for folic acid based upon their ethnic background. One study determined that in the Welsh population, about 12% of people have the TT genotype of the methylenetet-rahydrofolate reductase 677C → T mutation. Therefore, the study’s authors suggested that a folate-enrichment policy be formulated to help these individuals achieve intakes between 400 and 600 μg/d.13 In another study, women with the TT genotype appeared to benefit the most from folic acid supplementation intended to lower plasma total homocysteine.14 In Canada, women of First Nations origin had a higher risk of having an NTD-affected pregnancy than did white women. Although obesity and type 2 diabetes could have been the risk factors for these NTDs, other mechanisms that might be related to folate status should be explored within this population.15

Overall, the goal should be to increase red blood cell folate concentrations to greater than 905 nmol/L, a level associated with a low risk of having a child with an NTD. In women, a 400-μg daily dose of folic acid raised the red blood cell concentration to 1053 nmol/L from a baseline of 615 nmol/L after 12 weeks. This study also showed that a once-a-week folic acid supplement (2800 μg) also raised red blood cell folate concentrations, but not as effectively as a daily supplement.16 For women who have an intermediate to high risk of having an NTD-affected pregnancy, the Society of Obstetricians and Gynaecologists of Canada *recommends a daily intake of high-dose (4 to 5 mg) folic acid supplementation.17 Some studies have shown that lower doses of folic acid (300 μg or less) have the potential to lower total homocysteine concentrations, especially in those individuals who are in the higher range of homocysteine values.18,19 It is most important, however, that women of child-bearing age achieve adequate folate status through consumption of vegetables, fruit, and fortified grain products, and take folic acid in supplement form as a risk-reduction strategy.

Footnotes

  • Competing interests

    Dr Aldoori is employed by and Dr Ryan-Harshman received a grant to co-author this article from Wyeth Consumer Healthcare Inc.

  • ↵* New, more extensive clinical practice guidelines were published in the December 2007 issue of the

    Journal of Obstetrics and Gynaecology Canada20072912: 1003– 13
    OpenUrl
    .

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Steegers-Theunissen RP,
    2. Boers GH,
    3. Trijbels FJ,
    4. Finkelstein JD,
    5. Blom HJ,
    6. Thomas CM,
    7. et al
    . Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994;43(12):1475-80.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Mills JL,
    2. McPartlin JM,
    3. Kirke PN,
    4. Lee YJ,
    5. Conley MR,
    6. Weir DG,
    7. et al
    . Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 1995;345:791.
    OpenUrlPubMed
  3. ↵
    1. Green NS
    . Folic acid supplementation and prevention of birth defects. J Nutr 2002;132(8 Suppl):2356S-60S.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council vitamin study. Lancet 1991;338:131-7.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Ray JG,
    2. Meier C,
    3. Vermeulen MJ,
    4. Boss S,
    5. Wyatt PR,
    6. Cole DE
    . Association of neural tube defects and folic acid food fortification in Canada. Lancet 2002;360:2047-8.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Botto LD,
    2. Lisi A,
    3. Robert-Gnansia E,
    4. Eriskson JD,
    5. Vollset SE,
    6. Mastroiacovo P,
    7. et al
    . International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? BMJ 2005;330(7491):571. Epub 2005 Feb 18.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Robbins JM,
    2. Cleves MA,
    3. Collins HB,
    4. Andrews N,
    5. Smith LN,
    6. Hobbs CA
    . Randomized trial of a physician-based intervention to increase the use of folic acid supplements among women. Am J Obstet Gynecol 2005;192:1126-32.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Canfield MA,
    2. Collins JS,
    3. Botto LD,
    4. Williams LJ,
    5. Mai CT,
    6. Kirby RS,
    7. et al
    . Changes in the birth prevalence of selected birth defects after grain fortification with folic acid in the United States: Findings from a multi-state population-based study. Birth Defects Res A Clin Mol Teratol 2005;73(10):679-89.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Hall JG
    . Folic acid: the opportunity that still exists. CMAJ 2000;162:1571-2.
    OpenUrlFREE Full Text
  10. ↵
    Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. Washington, DC: National Academy Press; 1997.
  11. ↵
    1. Tice JA,
    2. Ross E,
    3. Coxson PG,
    4. Rosenberg I,
    5. Weinstein MC,
    6. Hunink MGM,
    7. et al
    . Cost-effectiveness of vitamin therapy to lower plasma homo-cysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA 2001;286:936-43.
    OpenUrlCrossRefPubMed
  12. ↵
    Centers for Disease Control and Prevention (CDC). Use of dietary supplements containing folic acid among women of childbearing age—United States, 2005. MMWR Morb Mortal Wkly Rep 2005;54:955-8.
    OpenUrlPubMed
  13. ↵
    1. Ashfield-Watt PAL,
    2. Pullin CH,
    3. Whiting JM,
    4. Clark ZE,
    5. Moat SJ,
    6. Newcombe RG
    . Methylenetetrahydrofolate reductase 677C → Tgenotype modulates homocyste -ineresponses to a folate-rich diet ora low-dosefolic acidsupplement: A randomized controlled trial. Am J Clin Nutr 2002;76:180-6.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Fohr IP,
    2. Prinz-Langenohl R,
    3. Brönstrup A,
    4. Bohlmann AM,
    5. Nau H,
    6. Berthold HK,
    7. et al
    . 5,10-Me thylenetetrahydrofolate reductase genotype determines the plasma homocysteine-lowering effect of supplementation with 5-methyltetrahydrofolate or folic acid in healthy young women. Am J Clin Nutr 2002;75:275-82.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Ray JC,
    2. Vermeulen MJ,
    3. Meier C,
    4. Cole DEC,
    5. Wyatt PR
    . Maternal ethnicity and risk of neural tube defects: a population-based study. CMAJ 2004;171:343-5.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Norsworthy B,
    2. Skeaff CM,
    3. Adank C,
    4. Green TJ
    . Effects of once-a-week or daily folic acid supplementation on red blood cell folate concentrations in women. Eur J Clin Nutr 2004;58:548-54.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Wilson RD,
    2. Davies G,
    3. Desilets V,
    4. Reid GJ,
    5. Summers A,
    6. Wyatt P,
    7. et al
    . The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003;25(11):959-73.
    OpenUrlPubMed
  18. ↵
    1. Brouwer IA,
    2. van Dusseldorp M,
    3. Thomas CMG,
    4. Duran M,
    5. Hautvast JGAJ,
    6. Eskes TKAB,
    7. et al
    . Low-dose folic acid supplementation decreases plasma homocysteine concentrations: a randomised trial. Indian Heart J 2000;52(7 Suppl):S53-8.
    OpenUrlPubMed
  19. ↵
    1. Venn BJ,
    2. Mann JI,
    3. Williams SM,
    4. Riddell LJ,
    5. Chisholm A,
    6. Harper MJ,
    7. et al
    . Assessment of three levels of folic acid on serum folate and plasma homocysteine: a randomised placebo-controlled double-blind dietary intervention trial. Eur J Clin Nutr 2002;56(8):748-54.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top

In this issue

Canadian Family Physician: 54 (1)
Canadian Family Physician
Vol. 54, Issue 1
1 Jan 2008
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Folic acid and prevention of neural tube defects
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Folic acid and prevention of neural tube defects
Milly Ryan-Harshman, Walid Aldoori
Canadian Family Physician Jan 2008, 54 (1) 36-38;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Folic acid and prevention of neural tube defects
Milly Ryan-Harshman, Walid Aldoori
Canadian Family Physician Jan 2008, 54 (1) 36-38;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Recommendations on folic acid supplementation
    • Footnotes
    • References
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Scurvy
  • Intraprofessional relationships
  • Question: Can you identify this condition?
Show more Current Practice

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • RSS Feeds

Copyright © 2021 by The College of Family Physicians of Canada

Powered by HighWire